Flyrcado

Flyrcado is an IV PET imaging agent for adults with known or suspected coronary artery disease. It highlights blood flow to the heart under rest or stress, helping doctors accurately detect ischemia or areas at risk of infarction.

Molecule Details :

  • Molecule Name :

    Flurpiridaz F 18
  • Innovator :

    GE HEALTHCARE INC
  • Approval Date :

    27-Sep-24
  • NCE-1 Date :

    27-Sep-28
  • NCE Date :

    27-Sep-29
  • Dosage Form :

    Intravenous Injection
  • Strength :

    5-55mCi-ML
  • Therapeutic Category :

    Diagnostic Agents
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    NA
  • 2026 :

    NA
  • 2027 :

    NA
  • 2028 :

    NA
  • 2029 :

    NA
  • 2030 :

    NA
  • 2031 :

    NA
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?